User talk:Filll: Difference between revisions
m →I don't get it: edit |
No edit summary |
||
Line 218: | Line 218: | ||
::::The help you could offer is balance. You're familiar with the dispute and the sources. The fact of your contributing would help solidify whatever consensus we arrive at, because we would know that your input was considered fairly. You also have insight into a current problem with the political climate here. You could help change that. Help make Wikipedia a welcoming place for experts by helping me to empower users to deal with tendentious editors and trolls. That's precisely what I'm trying to do. We may disagree about causes of the atmosphere which you describe as increasingly poisonous, but we both want to do something about it. -[[User:GTBacchus|GTBacchus]]<sup>([[User talk:GTBacchus|talk]])</sup> 02:32, 17 March 2008 (UTC) |
::::The help you could offer is balance. You're familiar with the dispute and the sources. The fact of your contributing would help solidify whatever consensus we arrive at, because we would know that your input was considered fairly. You also have insight into a current problem with the political climate here. You could help change that. Help make Wikipedia a welcoming place for experts by helping me to empower users to deal with tendentious editors and trolls. That's precisely what I'm trying to do. We may disagree about causes of the atmosphere which you describe as increasingly poisonous, but we both want to do something about it. -[[User:GTBacchus|GTBacchus]]<sup>([[User talk:GTBacchus|talk]])</sup> 02:32, 17 March 2008 (UTC) |
||
Oh, regarding the expert withdrawal page, I know about that. I've read it. I agree with [[User:Raymond arritt/Expert withdrawal#Only partially in jest|this]] view, and with [[User:Raymond arritt/Expert withdrawal#Undue weight to the success of Wikipedia|this]] one. Oh, [[User:Raymond arritt/Expert withdrawal#A less aggressive proposal|this]] is extremely good, too. I've actually left a comment there, and I have a question for you. You said: "''The powers that be including Arbcomm are dead set against this and have made it clear that they will desysop any admin who does this.''" Can you give me a link for that, please? -[[User:GTBacchus|GTBacchus]]<sup>([[User talk:GTBacchus|talk]])</sup> 02:51, 17 March 2008 (UTC) |
Oh, regarding the expert withdrawal page, I know about that. I've read it. I agree with [[User:Raymond arritt/Expert withdrawal#Only partially in jest|this]] view, and with [[User:Raymond arritt/Expert withdrawal#Undue weight to the success of Wikipedia|this]] one. Oh, [[User:Raymond arritt/Expert withdrawal#A less aggressive proposal|this]] is extremely good, too. I've actually left a comment there, and I have a question for you. You said: "''The powers that be including Arbcomm are dead set against this and have made it clear that they will desysop any admin who does this.''" Can you give me a link for that, please? -[[User:GTBacchus|GTBacchus]]<sup>([[User talk:GTBacchus|talk]])</sup> 02:51, 17 March 2008 (UTC) |
||
== Please put this on the Talk:Homeopathy Page and mention it is posted by me == |
|||
Dear Filll,<br> |
|||
Please put this on the Talk:Homeopathy Page and mention it is posted by me (or else the others may think I've bribed you); I'm not yet able to post there directly myself because the Page is semi-writeprotected.<br> |
|||
Here are some of the studies/clinical trials:-</p> |
|||
<b> |
|||
<p align="left">STUDIES OF THE ACTIVITY OF HOMEOPATHIC MEDICINES</p> |
|||
<div align="left"> |
|||
<table height="172" width="678" border="1"> |
|||
<tr> |
|||
<td width="171" height="9"><font size="1">ORIGINAL/TRANSLATED TITLE</font></td> |
|||
<td width="128" height="9">AUTHOR(S)</td> |
|||
<td width="84" height="9">PUBLICATION</td> |
|||
<td width="92" height="9">ACTIVITY</td> |
|||
<td width="203" height="9">STUDY</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="9"><font face="Optima-Bold" size="1"><b> |
|||
<p align="left">Inhibition of lymphoblast</b></font></b> <font face="Optima-Bold" size="1"><b>transformation |
|||
test (LTT) in</b></font> <font face="Optima-Bold" size="1"><b>phytohaemagglutinin |
|||
(PHA) with</b></font> <font face="Optima-Bold" size="1"><b>Phytolacca |
|||
americana in</b></font> <b><font face="Optima-Bold" size="1">homeopathic |
|||
dilution</font></b></p> |
|||
</td> |
|||
<td width="128" height="9"><font face="Optima" size="1"> |
|||
<p align="left">Colas H.,</p> |
|||
<p align="left">Aubin M.,</p> |
|||
<p align="left">Picard P.,</p> |
|||
<p align="left">Lebecq J.C.</font></p> |
|||
</td> |
|||
<td width="84" height="9"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Ann. Homéopat.</p> |
|||
<p align="left">Fr.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1975</font></b><font face="Optima" size="1">, |
|||
6: 1-11.</font></p> |
|||
</td> |
|||
<td width="92" height="9"><b> |
|||
<p align="left"><font face="Optima-Bold" size="1">Inhibitory</font></b></p> |
|||
</td> |
|||
<td width="203" height="9"> |
|||
<p align="left"><font face="Optima" size="1">Lymphoblast</p> |
|||
<p align="left">transformation</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="9"><font face="Optima-Bold" size="1"><b> |
|||
<p align="left">Inquiry into the limits of biological</b></font> <font face="Optima-Bold" size="1"><b>effects |
|||
of chemical compounds in</b></font> <font face="Optima-Bold" size="1"><b>tissue |
|||
culture. I. Low dose effects of</b></font> <b><font face="Optima-Bold" size="1">mercure |
|||
chloride</font></b></p> |
|||
</td> |
|||
<td width="128" height="9"><font face="Optima" size="1"> |
|||
<p align="left">Mansvelt J.D.,</p> |
|||
<p align="left">van Amons E.</font></p> |
|||
</td> |
|||
<td width="84" height="9"> |
|||
<p align="left"><i><font face="Optima-Oblique" size="1">Z. |
|||
Naturtorschung</font></i><font face="Optima" size="1">,</p> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">1975</font></b><font face="Optima" size="1">, 30:</p> |
|||
<p align="left">643-649.</font></p> |
|||
</td> |
|||
<td width="92" height="9"><b> |
|||
<p align="left"><font face="Optima-Bold" size="1">Inhibitory</font></b></p> |
|||
</td> |
|||
<td width="203" height="9"><font face="Optima" size="1"> |
|||
<p align="left">Lymphocyte</p> |
|||
<p align="left">growth</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="9"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">The effects of Belladonna and</font></b> <font face="Optima-Bold" size="1"><b>Ferrum |
|||
phosphoricum on the</b></font> <font face="Optima-Bold" size="1"><b>chemoluminescence |
|||
of human</b></font> <b><font face="Optima-Bold" size="1">poly-morphonuclear |
|||
neutrophils</font></b></p> |
|||
</td> |
|||
<td width="128" height="9"><font face="Optima" size="1"> |
|||
<p align="left">Poitevin B.,</p> |
|||
<p align="left">Aubin M.,</p> |
|||
<p align="left">Royer J.F.</font></p> |
|||
</td> |
|||
<td width="84" height="9"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Ann. Homéop. Fr.</font></i><font face="Optima" size="1">,</p> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">1983</font></b><font face="Optima" size="1">, 3: 5-12.</font></p> |
|||
</td> |
|||
<td width="92" height="9"><b> |
|||
<p align="left"><font face="Optima-Bold" size="1">Inhibitory</font></b></p> |
|||
</td> |
|||
<td width="203" height="9"><font face="Optima" size="1">Radical release</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Effect of aconitum and veratrum</p> |
|||
<p align="left">on the isolated perfused heart of</p> |
|||
<p align="left">the common eel </font></b><font face="Optima" size="1">(Anguilla |
|||
anguilla)</font></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Pennec J.P.,</p> |
|||
<p align="left">Aubin M.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Comp. Biochem.</p> |
|||
<p align="left">Physiol.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1984</font></b><font face="Optima" size="1">,</p> |
|||
<p align="left">776: 367-369.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1">Aconitine toxicity</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Elements of homeopathic</p> |
|||
<p align="left">pharmacology</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Aubin M.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Homéopathie</p> |
|||
<p align="left">Franç.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1984</font></b><font face="Optima" size="1">, |
|||
72:</p> |
|||
<p align="left">231- 235</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1">Aconitine toxicity</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">The effect of homeopathic</p> |
|||
<p align="left">preparations on the phagocyte</p> |
|||
<p align="left">activity of granulocytes. In vitro</p> |
|||
<p align="left">tests and double-blind controlled</p> |
|||
<p align="left">trials</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Wagner H.,</p> |
|||
<p align="left">Jurcic K.,</p> |
|||
<p align="left">Doenicke A.,</p> |
|||
<p align="left">Rosenhuber E.,</p> |
|||
<p align="left">Behrens N.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Arzneim.</p> |
|||
<p align="left">Forsch./Drug Res.</font></i><font face="Optima" size="1">,</p> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">1986</font></b><font face="Optima" size="1">, 36:</p> |
|||
<p align="left">1424-1425.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1">Phagocytosis</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Approach to quantitative analysis</p> |
|||
<p align="left">of the effect of Apis mellifica on</p> |
|||
<p align="left">the degranulation of human</p> |
|||
<p align="left">basophils cultivated in vitro</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Poitevin B.,</p> |
|||
<p align="left">Aubin M.,</p> |
|||
<p align="left">Benveniste J.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Innov. Tech. Biol.</p> |
|||
<p align="left">Med.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1986</font></b><font face="Optima" size="1">, |
|||
7:</p> |
|||
<p align="left">64-68.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Basophil</p> |
|||
<p align="left">degranulation</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">In vitro stimulation of human</font></b> <b><font face="Optima-Bold" size="1">granulocytes |
|||
and lymphocytes by</font></b> <font face="Optima-Bold" size="1"><b>pico- |
|||
and femtogram quantities of</b></font> <b><font face="Optima-Bold" size="1">cytostatic |
|||
agents</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Wagner H.,</p> |
|||
<p align="left">Kreher B.,</p> |
|||
<p align="left">Jurcic K.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><font face="Optima-Oblique" size="1"><i> |
|||
<p align="left">Arzneim.</i></font> <b><font face="Optima-Oblique" size="1"><i>Forsch./Drug |
|||
Res.</i></font><font face="Optima" size="1">,</font></b> <b><font face="Optima-Bold" size="1">1988</font><font face="Optima" size="1">, |
|||
38:</font></b> <b><font face="Optima" size="1">273-275.</font></b></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Lymphocyte</p> |
|||
<p align="left">growth</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Human basophil degranulation</font></b> <b><font face="Optima-Bold" size="1">triggered |
|||
by very dilute antiserum</font></b> <b><font face="Optima-Bold" size="1">against |
|||
IgE</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Davenas E.,</font> <font face="Optima" size="1"><b>Beauvais |
|||
F.,</b></font> <font face="Optima" size="1"><b>Amara J.,</b></font> <font face="Optima" size="1"><b>Robinson |
|||
M.,</b></font> <font face="Optima" size="1"><b>Miadonna A.,</b></font> <font face="Optima" size="1"><b>Tedeschi |
|||
A.,</b></font> <font face="Optima" size="1"><b>Pomeranz B.,</b></font> <font face="Optima" size="1"><b>Fortner |
|||
P.,</b></font> <font face="Optima" size="1"><b>Belon P.,</b></font> <font face="Optima" size="1"><b>Sainte-Laudy |
|||
J.,</b></font> <font face="Optima" size="1"><b>Poitevin B.,</b></font> <b><font face="Optima" size="1">Benveniste |
|||
J.</font></b></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Nature</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1988</font></b><font face="Optima" size="1">,</p> |
|||
<p align="left">333: 816-818.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Basophils</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><font face="Optima" size="1"> |
|||
<p align="left"></font><b><font face="Optima-Bold" size="1">In vitro |
|||
immunological</p> |
|||
<p align="left">degranulation of human basophils</p> |
|||
<p align="left">is modulated by lung histamine</p> |
|||
<p align="left">and Apis mellifica</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Poitevin B.,</p> |
|||
<p align="left">Davenas E.,</p> |
|||
<p align="left">Benveniste J.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Brit. J. Clin.</p> |
|||
<p align="left">Pharmacol.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1988</font></b><font face="Optima" size="1">,</p> |
|||
<p align="left">25: 439-444.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Basophil</p> |
|||
<p align="left">degranulation</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Cytotoxic agents as</p> |
|||
<p align="left">immunomodulators</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Wagner H.,</p> |
|||
<p align="left">Kreher B.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Proc. of the 3rd</p> |
|||
<p align="left">GIRI meeting</font></i><font face="Optima" size="1">,</p> |
|||
<p align="left">Paris, </font><b><font face="Optima-Bold" size="1">1989</font></b><font face="Optima" size="1">, |
|||
31-</p> |
|||
<p align="left">46.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Lymphocyte</p> |
|||
<p align="left">growth</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Contributions of fundamental</p> |
|||
<p align="left">research in homeopathy</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Boiron J.,</p> |
|||
<p align="left">Belon P.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Berl. J. Res. Hom.</font></i><font face="Optima" size="1">,</p> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">1990</font></b><font face="Optima" size="1">, 1: 34-35.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Basophil</p> |
|||
<p align="left">degranulation</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Synergism of action between</p> |
|||
<p align="left">indoleacetic acid (IAA) and highly</p> |
|||
<p align="left">diluted solutions of CaCO3 on the</p> |
|||
<p align="left">growth of oat coleoptiles</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1">Bornoroni C.</font></td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Berl. J. Res. Hom.</font></i><font face="Optima" size="1">,</p> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">1991</font></b><font face="Optima" size="1">, 1 (4/5):</p> |
|||
<p align="left">275-278.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Growth of plant</p> |
|||
<p align="left">cells</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Study of the action of</p> |
|||
<p align="left">Hahnemannian dilutions of</p> |
|||
<p align="left">mercury chloride on the mitotic</p> |
|||
<p align="left">index in animal cell cultures.</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Boiron J.,</p> |
|||
<p align="left">Abecassis J.,</p> |
|||
<p align="left">Cotte J.,</p> |
|||
<p align="left">Bernard A.M.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Ann. Homéop.</p> |
|||
<p align="left">Fr</font></i><font face="Optima" size="1">., </font><b><font face="Optima-Bold" size="1">1991</font></b><font face="Optima" size="1">, |
|||
23:</p> |
|||
<p align="left">43-49.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1">Hg toxicity</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Dual effects of formylpeptides on</p> |
|||
<p align="left">the adhesion of endotoxin-primed</p> |
|||
<p align="left">human neutrophils</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Bellavite P.,</p> |
|||
<p align="left">Chirumbolo S.,</p> |
|||
<p align="left">Lippi G.,</p> |
|||
<p align="left">Andrioli G.,</p> |
|||
<p align="left">Bonazzi L.,</p> |
|||
<p align="left">Ferro I.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Cell. Biochem.</p> |
|||
<p align="left">Funct.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1993</font></b><font face="Optima" size="1">, |
|||
11:</p> |
|||
<p align="left">231-239.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Cell adhesion</p> |
|||
<p align="left">(bact. pept.</p> |
|||
<p align="left">10-8-10-9)</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Effects of homeopathic</p> |
|||
<p align="left">preparations of organic acids and</p> |
|||
<p align="left">of minerals on the oxidative</p> |
|||
<p align="left">metabolism of human neutrophils</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Chirumbolo S.,</p> |
|||
<p align="left">Signorini A.,</p> |
|||
<p align="left">Bianchi I.,</p> |
|||
<p align="left">Lippi G.,</p> |
|||
<p align="left">Bellavite P.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Br. Hom. J.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1993</font></b><font face="Optima" size="1">,</p> |
|||
<p align="left">82: 227-244.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Leucocyte</p> |
|||
<p align="left">activation</p> |
|||
<p align="left">(metabolism)</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Platelets/endothelial cells</p> |
|||
<p align="left">interactions in presence of</p> |
|||
<p align="left">acetylsalicylic acid at ultra low</p> |
|||
<p align="left">dose</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Doutremepuich</p> |
|||
<p align="left">C.,</p> |
|||
<p align="left">Lalanne M.C.,</p> |
|||
<p align="left">Ramboer I.,</p> |
|||
<p align="left">Sertillanges</p> |
|||
<p align="left">M.N.,</p> |
|||
<p align="left">De Seze O.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Omeomed 92 (C.</p> |
|||
<p align="left">Bornoroni, ed.)</font></i><font face="Optima" size="1">,</p> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">1993</font></b><font face="Optima" size="1">, Editrice</p> |
|||
<p align="left">Compositori,</p> |
|||
<p align="left">Bologna:</p> |
|||
<p align="left">109-115.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Prostacyclin</p> |
|||
<p align="left">release</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Effect of high dilutions of epidermal</p> |
|||
<p align="left">growth factor (EGF) on </font><i><font face="Optima-BoldOblique" size="1">in |
|||
vitro</p> |
|||
</font></i><font face="Optima-Bold" size="1"> |
|||
<p align="left">proliferation of keratinocyte and</p> |
|||
<p align="left">fibroblast cell lines</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Fougeray S.,</p> |
|||
<p align="left">Moubry K.,</p> |
|||
<p align="left">Vallot N.,</p> |
|||
<p align="left">Bastide M.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Br. Hom. J.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1993</font></b><font face="Optima" size="1">,</p> |
|||
<p align="left">82: 124-125.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Growth of</p> |
|||
<p align="left">keratinocytes</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Effects of different homeopathic</p> |
|||
<p align="left">potencies of Lachesis on</p> |
|||
<p align="left">lymphocyte cultures obtained</p> |
|||
<p align="left">from rabbit blood</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Enbergs H.,</p> |
|||
<p align="left">Arndt G.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Biol. Tier., </font><b><font face="Optima-BoldOblique" size="1">1993</font></b><font face="Optima-Oblique" size="1">,</p> |
|||
<p align="left">4.</font></i></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Mitotic and</p> |
|||
<p align="left">immunostimulating</p> |
|||
<p align="left">activity (bact. pept</p> |
|||
<p align="left">10-5-10-6)</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">The effect of homeopathic</p> |
|||
<p align="left">potencies of housedust mite on</p> |
|||
<p align="left">the migration of house-dust sensitive</p> |
|||
<p align="left">human leukocytes</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Gibson S.L.,</p> |
|||
<p align="left">Gibson R.G.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Complement.</p> |
|||
<p align="left">Ther. Med.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1996</font></b><font face="Optima" size="1">,</p> |
|||
<p align="left">4: 169-171.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Leucocyte</p> |
|||
<p align="left">chemotaxis</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">The effects of Nux vomica</p> |
|||
<p align="left">Homaccord and Atropinum comp.</p> |
|||
<p align="left">on intestinal activity in vitro</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Kanui T.I.,</p> |
|||
<p align="left">Enbergs H.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Biol. Tier.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1996</font></b><font face="Optima" size="1">/1,</p> |
|||
<p align="left">43-47.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Contraction of</p> |
|||
<p align="left">intestinal muscles</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Application of flow cytometry to</p> |
|||
<p align="left">the analysis of the</p> |
|||
<p align="left">immunosuppressive effect of</p> |
|||
<p align="left">histamine dilutions on human</p> |
|||
<p align="left">basophil action: effect of</p> |
|||
<p align="left">cimetidine</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Sainte-Laudy J.,</p> |
|||
<p align="left">Belon P.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Inflamm. Res</font></i><font face="Optima" size="1">.,</p> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">1997</font></b><font face="Optima" size="1">, 46:</p> |
|||
<p align="left">S27-S28.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Basophil</p> |
|||
<p align="left">degranulation</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Effects of Podophillum pellatum</p> |
|||
<p align="left">compounds in various</p> |
|||
<p align="left">preparations and dilutions on</p> |
|||
<p align="left">human neutrophil functions in</p> |
|||
<p align="left">vitro</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Chirumbolo S.,</p> |
|||
<p align="left">Conforti A.,</p> |
|||
<p align="left">Lussignoli S.,</p> |
|||
<p align="left">Metelmann H.</p> |
|||
<p align="left">et Al.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Br. Hom. J</font></i><font face="Optima" size="1">., </font><b><font face="Optima-Bold" size="1">1997</font></b><font face="Optima" size="1">;</p> |
|||
<p align="left">86-16.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Release of</p> |
|||
<p align="left">superoxides</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><i><font face="Optima-BoldOblique" size="1"> |
|||
<p align="left">In vivo </font></i><font face="Optima-Bold" size="1">and |
|||
</font><i><font face="Optima-BoldOblique" size="1">in vitro </font></i><font face="Optima-Bold" size="1">studies |
|||
on the</p> |
|||
<p align="left">efficiency of potentized and nonpotentized</p> |
|||
<p align="left">substances</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Harisch G.,</p> |
|||
<p align="left">Dittmann J.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">BT, </font></i><b><font face="Optima-Bold" size="1">1997</font></b><font face="Optima" size="1">, |
|||
2;</p> |
|||
<p align="left">40-46.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Difference between</p> |
|||
<p align="left">potentised and</p> |
|||
<p align="left">non-potentised</p> |
|||
<p align="left">substances</font></p> |
|||
</td> |
|||
<td width="203" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">In vivo </font></i><font face="Optima" size="1">and </font><i><font face="Optima-Oblique" size="1">in</p> |
|||
<p align="left">vitro </font></i><font face="Optima" size="1">study; |
|||
basic</p> |
|||
<p align="left">research</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Experiments with the effects of</p> |
|||
<p align="left">Ubichinon-Injeel and strong</p> |
|||
<p align="left">Ubichinon-Injeel on an acellular</p> |
|||
<p align="left">system</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Harisch G.,</p> |
|||
<p align="left">Dittmann J.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1997</font></b><font face="Optima" size="1">, |
|||
3;</p> |
|||
<p align="left">99-104.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Different effects of</p> |
|||
<p align="left">associations of</p> |
|||
<p align="left">various potencies and</p> |
|||
<p align="left">individual potencies</font></p> |
|||
</td> |
|||
<td width="203" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">In vitro </font></i><font face="Optima" size="1">study;</p> |
|||
<p align="left">basic research</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Efficacy of the homeopathic drugs</p> |
|||
<p align="left">Suis and Arnica comp.-Heel® on</p> |
|||
<p align="left">lymphocyte and phagocyte</p> |
|||
<p align="left">activity</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1">Enbergs H.</font></td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1998</font></b><font face="Optima" size="1">, |
|||
1;</p> |
|||
<p align="left">3-11.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Effect of</p> |
|||
<p align="left">organotherapeutics</p> |
|||
<p align="left">and Arnica comp. -</p> |
|||
<p align="left">Heel® on immune</p> |
|||
<p align="left">system cells</font></p> |
|||
</td> |
|||
<td width="203" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">In vitro </font></i><font face="Optima" size="1">study;</p> |
|||
<p align="left">basic research</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Influence of dilutions and</p> |
|||
<p align="left">potencies of cAMP on different</p> |
|||
<p align="left">enzymatic systems</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Harisch G.,</p> |
|||
<p align="left">Dittmann J.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1998</font></b><font face="Optima" size="1">, |
|||
2;</p> |
|||
<p align="left">55-62.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Effects of dilutions</p> |
|||
<p align="left">and potencies of</p> |
|||
<p align="left">cAMP on some</p> |
|||
<p align="left">enzymatic activities</font></p> |
|||
</td> |
|||
<td width="203" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">In vitro </font></i><font face="Optima" size="1">study;</p> |
|||
<p align="left">basic research</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Studies of the principles of</p> |
|||
<p align="left">homeopathy; the changeover</p> |
|||
<p align="left">from </font><i><font face="Optima-BoldOblique" size="1">in |
|||
vivo </font></i><font face="Optima-Bold" size="1">to </font><i><font face="Optima-BoldOblique" size="1">in |
|||
vitro</p> |
|||
</font></i><font face="Optima-Bold" size="1"> |
|||
<p align="left">experimental research</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Harisch G.,</p> |
|||
<p align="left">Dittmann J.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1998</font></b><font face="Optima" size="1">, |
|||
3;</p> |
|||
<p align="left">98-103.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Potentised and</p> |
|||
<p align="left">non-potentised</p> |
|||
<p align="left">dilutions are</p> |
|||
<p align="left">equally effective,</p> |
|||
<p align="left">but have different</p> |
|||
<p align="left">actions</font></p> |
|||
</td> |
|||
<td width="203" height="8"> |
|||
<p align="left"><font face="Optima-Oblique" size="1">B</font><font face="Optima" size="1">asic |
|||
research</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><font face="Optima-Bold" size="1"><b> |
|||
<p align="left">Determination of the activity of</b></font> <b><font face="Optima-Bold" size="1">acid |
|||
phosphatase with cAMP at</font></b> <b><font face="Optima-Bold" size="1">various |
|||
potencies</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Harisch G.,</p> |
|||
<p align="left">Dittmann J.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">BM, </font></i><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">, |
|||
1; 4-8.</font></td> |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Different effects on</font> <font face="Optima" size="1">enzymatic |
|||
activity</font></p> |
|||
</td> |
|||
<td width="203" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">In vitro </font></i><font face="Optima" size="1">study;</p> |
|||
<p align="left">basic research</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Contribution to study of the</p> |
|||
<p align="left">efficacy of homeopathic potencies</p> |
|||
<p align="left">of phosphorus</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1">Gomez J.C.</font></td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">BT, </font></i><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">, |
|||
2;</p> |
|||
<p align="left">53-57.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Effect of different</p> |
|||
<p align="left">potencies of</p> |
|||
<p align="left">phosphorus</font></p> |
|||
</td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Tests on guinea</p> |
|||
<p align="left">pigs</font></p> |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Determination of the activity of</p> |
|||
<p align="left">acid phosphatase in the presence</p> |
|||
<p align="left">of Ubichinon comp.</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Harisch G.,</p> |
|||
<p align="left">Dittmann J.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">, |
|||
4;</p> |
|||
<p align="left">188-194.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Effect of enzymatic</p> |
|||
<p align="left">activity of</p> |
|||
<p align="left">homeopathic</p> |
|||
<p align="left">medicine</font></p> |
|||
</td> |
|||
<td width="203" height="8"><font face="Optima-Oblique" size="1">B</font><font face="Optima" size="1">asic |
|||
research</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Biochemical efficacy of</p> |
|||
<p align="left">homeopathic and electronic</p> |
|||
<p align="left">preparations of D8 potassium</p> |
|||
<p align="left">cyanate</font></b></p> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Dittmann J.,</p> |
|||
<p align="left">Kanapin H.,</p> |
|||
<p align="left">Harisch G.</font></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">FKM, </font></i><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">, |
|||
6;</p> |
|||
<p align="left">15-18.</font></p> |
|||
</td> |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Homeopathic</p> |
|||
<p align="left">potentisation is</p> |
|||
<p align="left">more effective than</p> |
|||
<p align="left">electronic</p> |
|||
<p align="left">potentisation</font></p> |
|||
</td> |
|||
<td width="203" height="8"><font face="Optima-Oblique" size="1">B</font><font face="Optima" size="1">asic |
|||
research</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Osteoporosis in vitro in rat tibiaderived</p> |
|||
<p align="left">osteoblasts is promoted</p> |
|||
<p align="left">by the homeopathic preparation,</p> |
|||
<p align="left">FMS Calciumfluor</font></b></td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Palermo C.,</p> |
|||
<p align="left">Filanti C.,</p> |
|||
<p align="left">Poggi S.,</p> |
|||
<p align="left">Manduca P.</font></td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Cell Biol Int</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">,</p> |
|||
<p align="left">23(1): 31-40.</font></td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Stimulant</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Osteogenesis</p> |
|||
<p align="left">(trial with</p> |
|||
<p align="left">compound drug)</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="32" rowspan="2"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Thin-layer chromatography (TLC)</p> |
|||
<p align="left">of homeopathic active</p> |
|||
<p align="left">constituents</font></b></td> |
|||
<td width="128" height="32" rowspan="2"><font face="Optima" size="1">Schmolz |
|||
M.</font></td> |
|||
<td width="84" height="32" rowspan="2"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">, |
|||
5;</p> |
|||
<p align="left">248-250.</font></td> |
|||
<td width="92" height="16"><font face="Optima" size="1"> |
|||
<p align="left">Constituents of</font> <font face="Optima" size="1">Arnica |
|||
comp.-</font> <font face="Optima" size="1">Heel® ointment:</font> <font face="Optima" size="1">electrophoresis</font> |
|||
<font face="Optima" size="1">accelerates their</font> <font face="Optima" size="1">skin |
|||
penetration.</font> </td> |
|||
<td width="203" height="32"><font face="Optima" size="1">Basic research</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="92" height="16"><font face="Optima" size="1">Effect of</font> <font face="Optima" size="1">homeopathic</font> |
|||
<font face="Optima" size="1">constituents on</font> <font face="Optima" size="1">enzymatic |
|||
activity.</font></td> |
|||
<td width="203" height="4"><font face="Optima" size="1">Basic research</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Efficacy of a potentised</p> |
|||
<p align="left">homeopathic drug in reducing</p> |
|||
<p align="left">cytotoxic effects produced by</p> |
|||
<p align="left">arsenic trioxide in mice</font></b></td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Datta S.,</p> |
|||
<p align="left">Mallick P.,</p> |
|||
<p align="left">Bukhsh A.R.</font></td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Complement Ther</p> |
|||
<p align="left">Med</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1999 |
|||
</font></b><font face="Optima" size="1">Jan;</p> |
|||
<p align="left">7 (8): 62-75 </font><b><font face="Optima-Bold" size="1">(a).</font></b></td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Arsenic trioxide</p> |
|||
<p align="left">toxicity</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Efficacy of a potentised</p> |
|||
<p align="left">homeopathic drug in reducing</p> |
|||
<p align="left">cytotoxic effects produced by</p> |
|||
<p align="left">arsenic trioxide in mice</font></b></td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Datta S.,</p> |
|||
<p align="left">Mallick P.,</p> |
|||
<p align="left">Bukhsh A.R.</font></td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Complement Ther</p> |
|||
<p align="left">Med</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1999 |
|||
</font></b><font face="Optima" size="1">Sep;</p> |
|||
<p align="left">7 (3): 156-63 </font><b><font face="Optima-Bold" size="1">(b).</font></b></td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Arsenic trioxide</p> |
|||
<p align="left">toxicity</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><font face="Optima-Bold" size="1"><b> |
|||
<p align="left">Non-cytotoxic antiviral action of</b></font> <font face="Optima-Bold" size="1"><b>a |
|||
homeopathic drug</b></font></td> |
|||
<td width="128" height="8"><font face="Optima" size="1">Heine H.</font></td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Ärzteitschrift für</p> |
|||
<p align="left">Neturheilverfahre</font></i><font face="Optima" size="1">,</p> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">2000</font></b><font face="Optima" size="1">; 41: 542-7.</font></td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td> |
|||
<td width="203" height="8"><font face="Symbol" size="1"> |
|||
<p align="left">ã </font><font face="Optima" size="1">interferon</p> |
|||
<p align="left">synthesis</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Efficacy of a potentised</p> |
|||
<p align="left">homeopathic drug in reducing</p> |
|||
<p align="left">cytotoxic effects produced by</p> |
|||
<p align="left">arsenic trioxide in mice</font></b></td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Kundu S.N.,</p> |
|||
<p align="left">Mitra K.,</p> |
|||
<p align="left">Khuda</p> |
|||
<p align="left">Bukhsh A.R.</font></td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Complement Ther</p> |
|||
<p align="left">Med </font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">2000 |
|||
</font></b><font face="Optima" size="1">Sep;</p> |
|||
<p align="left">1 (3): 157-65.</font></td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Arsenic trioxide</p> |
|||
<p align="left">toxicity</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Stimulatory effect of some plant</p> |
|||
<p align="left">extracts used in homeopathy on</p> |
|||
<p align="left">the phagocytosis induced</p> |
|||
<p align="left">chemiluminescence of</p> |
|||
<p align="left">polymorphonuclear leukocytes</font></b></td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Crocnan D.,</p> |
|||
<p align="left">Greabu M.,</p> |
|||
<p align="left">Olinescu R.</font></td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Rocz Akad Med</p> |
|||
<p align="left">Biochemist</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">2000</font></b><font face="Optima" size="1">;</p> |
|||
<p align="left">45: 246-254.</font></td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Phagocytosis</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Difference between the efficacy</p> |
|||
<p align="left">of single potencies and chords</font></b></td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Dittmann J.,</p> |
|||
<p align="left">Harisch G.</font></td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">2000</font></b><font face="Optima" size="1">, |
|||
1;</p> |
|||
<p align="left">18-23.</font></td> |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
<p align="left">Potency chords are</p> |
|||
<p align="left">more effective than</p> |
|||
<p align="left">single potencies</font></td> |
|||
<td width="203" height="8"><font face="Optima" size="1">Basic research</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="28"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Influence of some homeopathic</p> |
|||
<p align="left">drugs on the catalytic activity of</p> |
|||
<p align="left">uricase, acid phosphatase and the</p> |
|||
<p align="left">cytosol glutathion-S-transferase</font></b></td> |
|||
<td width="128" height="28"><font face="Optima" size="1"> |
|||
<p align="left">Dittmann J.,</p> |
|||
<p align="left">Kanapin H.,</p> |
|||
<p align="left">Harisch G.</font></td> |
|||
<td width="84" height="28"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">2000</font></b><font face="Optima" size="1">, |
|||
3;</p> |
|||
<p align="left">125-131</font></td> |
|||
<td width="92" height="28"><font face="Optima" size="1"> |
|||
<p align="left">Effect of D8</p> |
|||
<p align="left">potencies on three</p> |
|||
<p align="left">different enzymatic</p> |
|||
<p align="left">systems</font></td> |
|||
<td width="203" height="28"><font face="Optima" size="1">Basic research</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="37"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Influence of some homeopathic</p> |
|||
<p align="left">drugs on the catalytic activity of</p> |
|||
<p align="left">cAMP-dependent protein kinases</font></b></td> |
|||
<td width="128" height="37"><font face="Optima" size="1"> |
|||
<p align="left">Dittmann J.,</p> |
|||
<p align="left">Kanapin H.,</p> |
|||
<p align="left">Harisch G.</font></td> |
|||
<td width="84" height="37"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">2000</font></b><font face="Optima" size="1">, |
|||
6;</p> |
|||
<p align="left">289-296.</font></td> |
|||
<td width="92" height="37"><font face="Optima" size="1"> |
|||
<p align="left">Effect of different</p> |
|||
<p align="left">potencies of 5</p> |
|||
<p align="left">substances on</p> |
|||
<p align="left">enzymatic activity</font></td> |
|||
<td width="203" height="37"><font face="Optima" size="1">Basic research</font></td> |
|||
</tr> |
|||
<tr> |
|||
<td width="171" height="38"><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">Neuroprotection from glutamate</p> |
|||
<p align="left">toxicity with ultra-low dose</p> |
|||
<p align="left">glutamate</font></b></td> |
|||
<td width="128" height="38"> |
|||
<p align="left"><font face="Optima" size="1">Jonas W.,</p> |
|||
<p align="left">Lin Y.,</p> |
|||
<p align="left">Zortella F.</font></td> |
|||
<td width="84" height="38"><i><font face="Optima-Oblique" size="1"> |
|||
<p align="left">Neuroreport</font></i><font face="Optima" size="1">,</p> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
<p align="left">2001 </font></b><font face="Optima" size="1">Feb 92; 12</p> |
|||
<p align="left">(2): 335-9.</font></td> |
|||
<td width="92" height="38"><b><font face="Optima-Bold" size="1">Protective</font></b></td> |
|||
<td width="203" height="38"><font face="Optima" size="1">Glutamate |
|||
toxicity</font></td> |
|||
</tr> |
|||
</table> |
|||
</div> |
|||
<font face="Optima" size="1"> |
|||
<p align="left"> </p> |
|||
<p align="left">KEY: BT = Biomedical Therapy</p> |
|||
<p align="left">BM = Biologische Medizin</p> |
|||
<p align="left">FKM = Forschung Komplementär Medizin</p> |
|||
</font></font></font></font></font></font></font></font>[[User:Ramaanand|Ramaanand]] ([[User talk:Ramaanand|talk]]) 02:14, 17 March 2008 (UTC)Dr.Jhingadé |
Revision as of 03:09, 17 March 2008
Given the level of dysfunction that has come to prevail on Wikipedia, the most appropriate course for a principled scientist is to withdraw from the project.
The bureaucracy should either take corrective steps to fix this situation, or else suffer the eventual loss of huge amounts of valuable talent and volunteered resources.
If you agree with this statement, post it to your pages, and pass it on. (discuss this here)
Barnstars Humor
|
Fact, theory and a new journal
This article is likely to interest you, found via the links shown at Talk:evolution.... dave souza, talk 00:25, 29 December 2007 (UTC)
Evolution resource
Just wanted to share this link, it's for the new "big" textbook on Evolution. Amazingly, most of the figures from the book are available free of charge on the web page, so it's a really useful resource. It may be a useful external link on some articles. I've added it to a few, maybe you can see further uses.
http://www.evolution-textbook.org/
I also messaged Dave Souza and Adam Cuerden. Samsara (talk • contribs) 19:01, 26 January 2008 (UTC) diff=187720119&oldid=187578481 :)] David D. (Talk) 17:33, 29 January 2008 (UTC)
Expert withdrawal
I'm not sure what you want to be shown, but the Ilena/Fyslee Arbcom has multiple, blatant examples by multiple editors. What do you want to be shown? Editors arguing that it is harassment to point out their improper behavior because others have similar behavior? Editors arguing that they should be allowed to harass editors accused of misbehavior? Editors repeatedly gaming the system? It's all in the arbcom. Worse, it's all still being done by editors that were part of that arbcom. --Ronz (talk) 17:20, 30 January 2008 (UTC)
From [1]
During this period between the world wars, sightings were reported and searches launched for, among others, the snoligostus, the ogopogo, the Australian bunyip, the whirling wimpus, the rubberado, the rackabore, and the cross-feathered snee. These sound like some interesting creatures that deserve articles on WP! The only one I know of is the ogopogo, although I have never seen it, even though I have been to Lake Okanagan many times. ...--Filll (talk) 17:55, 7 February 2008 (UTC)
NPOV Challenge
I hereby challenge anyone who is not in favor of mainstream science, but promotes alternative medicine or pseudoscience or magic or mysticism or the supernatural or ghosts to tell me how they interpret NPOV, and why the SPOV proponents are wrong about NPOV. Tell me why there should be little if any critical material in pseudoscience and alternative medicine articles for example. This is your chance to change Wikipedia. Write an essay. --Filll (talk) 07:04, 1 March 2008 (UTC)
- Filll, you are talking to yourself here. This is not good. Also I resent your statements about the ruling class on the NPOV noticeboard. Please do not disrupt Wikipedia to make a point (don't know which that could be). If you have a quote for your assertion, please provide it. I thank you in advance. — Xiutwel ♫☺♥♪ (speech has the power to bind the absolute) 12:37, 1 March 2008 (UTC)
- If you don't know what the alleged point could be, how can you assume he's disrupting WP to make one? •Jim62sch•dissera! 13:12, 1 March 2008 (UTC)
Xiutwel, I am not even sure what that point is either. And how I disrupted WP on that noticeboard. Perhaps you could be more specific?--Filll (talk) 16:08, 1 March 2008 (UTC)
- Oh yes, now I see what you have supposedly been offended by. No, I stand by that statement. For more details, please see the relevant MH Arbcomm ruling, along with the two RfCs (one of which was deleted so you have to get it back). At least two administrators left or went on very long hiatus because of it. It is clear from the recent attitudes that I have seen expressed that WP:CIVIL is more important than all other WP principles, even WP:NPOV. For details, see the Expert Withdrawal discussion at User:Raymond arritt/Expert withdrawal. I am not the only one who has noticed. Literally dozens of others have as well. Come to the Expert Withdrawal page at User:Raymond arritt/Expert withdrawal and give your opinion on the matter if you are offended. If you are offended by the matter, then that is good; you should be. I am offended by it.--Filll (talk) 16:15, 1 March 2008 (UTC)
I do believe that the situation is exactly as I described: [2]. There is a price to making WP:CIVIL the main if not the sole policy that is being enforced. So be it... If those of you that are in power want to get rid of NPOV, then that is what will happen. I just would like you to make a formal announcement of the DEATH of NPOV first so those of us who thought it was a useful policy do not make fools of ourselves trying to advocate NPOV. --Filll (talk) 20:08, 1 March 2008 (UTC)
Expert withdrawal
Hi, I'm thinking of writing a piece for the Signpost about the Expert withdrawal discussion, and I'm trying to figure out how and why it originated. Were you the originator of this movement? Would you mind explaining in a few words what led you to this rather extreme measure, and what do you believe should be done in order to alleviate the problem? --Zvika (talk) 09:34, 1 March 2008 (UTC)
Unsolicited advice
"Brevity is the soul of wit." - W. Shakespeare (from Hamlet, IIRC) Raymond Arritt (talk) 20:31, 2 March 2008 (UTC)
Yeah just what I was thinking. I gotta work on succinctness. Or at least summaries.--Filll (talk) 20:40, 2 March 2008 (UTC)
- I don't really know why you bother with it. Leave the POV pushers to push their version of NPOV with optional N. You're going to get an ulcer (which can be treated with homeopathic solutions I'm sure...). Shot info (talk) 02:31, 3 March 2008 (UTC)
- ... well, maybe with ranitidine bismuth citrate taken with a homeopathic solution... :) Jay*Jay (talk) 03:26, 3 March 2008 (UTC)
After I read a good chunk of the Martinphi file, I realized their efforts are all just a load of nonsense. And to try to improve things is just a waste of time in this case.--Filll (talk) 03:33, 3 March 2008 (UTC)
- So would that be the Martinphile? :-) Shot info (talk) 05:45, 3 March 2008 (UTC)
Exactly.--Filll (talk) 12:14, 3 March 2008 (UTC)
Article you could propose for translation
In the german wikipedia there is an article about homeopathy in the time of the nazi dictorship. See [3]. Nazis tried to promote a new german medicine, which should include homeopathy, but gave up on that idea in 1939 after the results where disatorous. --80.133.146.251 (talk) 23:18, 3 March 2008 (UTC)
- Interesting. Thanks.--Filll (talk) 23:27, 3 March 2008 (UTC)
Translation
I have responded to your query regarding Homeopathy at my talk page. You may want to look at it. Thanks, Shyam (T/C) 09:32, 6 March 2008 (UTC)
Conventional "homeopathic" treatments
Many standard medical practices like prescribing ritalin and adderall for ADHD, heparin for IBD, vaccinations, hypnotics to prevent falls among the elderly, and allergy treatments are homeopathic, in that they involve treatment with something that produces the same symptoms as the disease.--Filll (talk) 21:46, 7 March 2008 (UTC)
- As I said, that really is a very good point. We would need to find a good source that makes this relationship as you have, but it's very true. There is no reason for people to be skeptical of low potency homeopathy, at all. High potencies are another thing. —Whig (talk) 22:50, 7 March 2008 (UTC)
Suggested changes in the WMF privacy policy
Hello,
I posted some suggestions for changes in the WMF privacy policy at the WMF site: [4]. The gist of the suggestions is to institute a requirement for notifying those registered users whose identifying info is being sought by subpoenas in third-party lawsuits. These suggestions are motivated in large part by a discussion that took place in January 2008 at the Village Pump (Policy) page [5] in relation to an incident where identifying IP data of sixteen Wikipedia users was released in response to such a subpoena. I also left a note about these proposal at Village Pump, WP:Village_pump_(policy)#Suggestions_for_changes_in_the_WMF_privacy_policy. Since you have participated in the January Village Pump discussion, I hope that you will contribute to the discussion of the current suggestions at the WMF website, [6]. Regards, Nsk92 (talk) 12:47, 8 March 2008 (UTC)
"OR"
If anyone ever tells me that converting 0.35 to 35% is "original research", I will respond that he should be ashamed of himself. Reading, writing, and 'rithmetic are taught in elementary school. What you were taught in elementary school is not your "original research". Michael Hardy (talk) 20:17, 6 March 2008 (UTC)
- Well it has happened where I have had a long fight with an admin who claimed that converting numbers like 312/783 into percentages is WP:OR. And now I am dealing with a slightly more complicated situation, but again being told that it is OR. And when I read math and physics pages, I see that people do all kinds of calculations and manipulations with seemingly no problem. Oh brother...--Filll (talk) 21:27, 6 March 2008 (UTC)
- Who was that administrator? Michael Hardy (talk) 01:18, 7 March 2008 (UTC)
Where is this discussion? Michael Hardy (talk) 00:55, 9 March 2008 (UTC)
- This was on Level of support for evolution. And the admin was violet/riga. The article is still a mess and I have not bothered to correct his vandalism (and that of a few other passing editors who even ruined the quotes from publications to push their agenda), since I am rewriting the article and placing most of the data into better organized tables to be shorter and easier to absorb for readers. I am working on other stuff at the moment but I will get back to that article.--Filll (talk) 01:04, 9 March 2008 (UTC)
Comment on WP:AN
Hi, Filll. I have added some comments in response to the questions from Dlabtot (sp?) about the ArbCom prioritising of civility over anything else. I have noted that I was not meaning to speak on your behalf, but I thought I should let you know in case you want to have a look and / or make a comment. Jay*Jay (talk) 01:51, 9 March 2008 (UTC)
Comments on potency rewrite
Leaving comments here, as the page is already in Talk space. Now, when it comes to examples of dilutions, it seems that (judging by some of my back-of-the-envelope calculations) it's assumed that you're starting off with one mole of the solute. For instance, let's say you have one liter of a one molar solution. This is typically about the scale you'll find for most common solutions, so it makes some sense. Homeopaths rarely bother with doing volume dilutions, so basing the examples off of these is misleading. Most of the time, they don't even bother being exact with the starting amount (after all, what does it matter?). So I think for the purpose of clarity and matching previous examples given, we should just go ahead assuming we start with a one molar solution. Aside from Yilloslime on Talk:Homeopathy, this seems to be the common assumption. (You can check for yourself that starting this way gives results matching those of the examples, and we also don't have to muddy the issue with mentioning what the material is, specifying its density, etc.). --Infophile (Talk) (Contribs) 22:03, 10 March 2008 (UTC)
- The reason I did it with densities and molar masses is that it is more general, and I believe that if we just specify "one mole" few of our readers will be able to figure out how much that is. I also believe that putting the extra details in the footnotes will help people trying to understand the situation, but they will not be required to read the footnotes to get the general gist of the text. I also do not think homeopaths do anything with moles or 1 molar solutions etc, and I think specifying "1 molar solutions" will be confusing the readers. I think homeopaths do volume volume percentage dilutions, according to my reading of their literature. Different materials will produce different numbers of molecules in a given volume of remedy after homeopathic dilution, depending on what their densities and molar masses are. I will however, try to a different version using some of the ideas you suggest and see what it looks like.--Filll (talk) 00:24, 11 March 2008 (UTC)
- Also I think 1 liter for an initial quantity of the therapeutic material is a lot unless this is being produced in an industrial process, and even then I have my doubts about that quantity from what I know of the literature and technology used to produce these remedies. Sounds misleading to me.--Filll (talk) 00:30, 11 March 2008 (UTC)
- Filll, it could use a little word-smithing but overall it looks pretty good. I think I have a solution to the "molarity of the mother tincture" issue that doesn't require assuming it's 1M or using a specific example like NaCl. And that is: rather than discussing the number of molecules of the "active" ingredient left in the final dilution, we could instead discuss the number of molecules of the mother tincture (i.e. the "active" ingredient + the alcohol) that remain in the final dilution. Regardless of the nature of the mother tincture, it's mostly just alcohol (or alcohol/water), right? Whether it's 1M or 0.1M, or contains small amounts of myriad compounds, the overwhelming majority of molecules that are floating around are still just alcohol molecules. So instead of using 1M as our starting concentration, we could just use the molarity of pure alcohol (~17 mol/L for EtOH) and change the text so it says "there would only be xxx molecules of the mother tincture remaining in yyy volume of zzzC dilution." What do you think of that? Yilloslime (t) 05:00, 11 March 2008 (UTC)
- Oh and I tend to agree with what you're saying above about leaving the gory details of molarity, etc., out the text, lest they confuse people needlessly. Footnoting them seems best.Yilloslime (t) 05:04, 11 March 2008 (UTC)
- Oh, it's fine leaving the details out; it's just that most of the time people have made these examples, they seem to be treating it like I did. It would be best to stick to these for NOR purposes, if nothing else. We can still keep the text simple, and just describe our assumptions in the footnotes. --Infophile (Talk) (Contribs) 20:24, 11 March 2008 (UTC)
Another Venue
Filll, I would appreciate it if you would calm down. I was not ranting, merely responding to statements similar to those who do support evolution have made in the past. If you want me to stop, ask on my page, don't repeatedly respond with comments on my "ranting," or "preaching." I have hoped to disassociate myself with that sort of creationist crowd. By the way, you don't know what "sort of creationism" I do believe in. If you wish to respond to my comments, or address any other comments or criticism towards me, please use my talk page. If you can convince me my comments are inflamatory, I will remove them. ---G.T.N. (talk) 03:01, 11 March 2008 (UTC)
- I would appreciate it if you would calm down and not pollute the talk pages of those articles with irrelevant inaccurate material. No the whole world does not believe in "creationism" and evolution is not some evil theory started in Ancient Greece or associated with the Tower of Babel or some other nonsense. Those are creationist canards and you look ridiculous parroting them. Care to tell me how the Buddhists are creationists? Most Jews? The Muslims? The Catholics? Native Americans? Australian Aborigines? Chinese Animists? Hindus? Sure some have creation myths, but they are so different from the fundamentalist Christian one that it is not even funny. And most have no problem with accepting evolution. Some even claim their creation myths include evolution (like many Hindus). Some claim that their coreligionists came up with evolution centuries before Darwin (like many Moslems). Most Americans see no conflict between Christianity and evolution. Most Christians see no conflict between Christianity and evolution. Only a teeny tiny minority who have been lead into confused denial, mostly in the United States, subscribes to this crazy notion.
- You do not have to remove your comments since they are irrelevant. They will just be archived and we can all forget them. But it is sort of silly to come to a page and respond to posts that are months old and lecture the people who posted them to not preach, when you are preaching yourself. It is even worse when a large fraction of what you are spouting makes no sense and is just random creationist junk.
- The original post of mine you objected to was me responding to someone writing about what happened "before" the cosmic egg (by which I presume they mean the big bang). Even the fact that they spew this sort of silliness tells me that they have no idea what they are talking about; there was no before since the big bang created time itself. But it is hardly worth responding to these ignorant statements except to discourage people from posting nonsense and to maybe make some positive contributions. But few if any ever do. They are not here for that.--Filll (talk) 08:18, 11 March 2008 (UTC)
Also, I would be careful who you are lecturing and engaging in fights with on the talk pages. You also have posted right in the middle of someone else's post, which is a complete no-no.--Filll (talk) 08:27, 11 March 2008 (UTC)
- Hello Filll. I think you are against creationism. At the same time, you are religious. How is this possible? I am a Humanist. I am a little confused about your views. Regards, Masterpiece2000 (talk) 03:27, 12 March 2008 (UTC)
Actually, that is the position of most Christians and even most American Christians, most Jews, and many Muslims, and most Hindus, most Catholics, most Buddhists, etc. If you believe otherwise, you have fallen into the fallacious thinking traps laid out for you by the fundamentalists and creationists.--Filll (talk) 03:42, 12 March 2008 (UTC)
- Well, Filll, I don't believe in creationism. Are you suggesting that most American Christians are against creationism? I don't think so. I am a non-American. If that were true, then GW Bush should not have won the re-election in 2004? GW Bush is a creationist and an irrational person. Can you please explain your position on creationism and religion clearly? Regards, Masterpiece2000 (talk) 08:56, 12 March 2008 (UTC)
Frankly, there is no reason I should have to. But I think biblical literalism, which is the root of most creationism, is just ludicrous and unreasonable. And so do most Christians. It has been strictly discouraged in the Catholic Church for centuries, for example. If you want to look at statistics, look at level of support for evolution. I am not even sure that Bush is much of a creationist; I think he tries to keep a large voting block reasonably tranquil.--Filll (talk) 12:47, 12 March 2008 (UTC)
The Martinphi-ScienceApologist Interview
What is the role of science in producing authoritative knowledge? How should Wikipedia report on pseudoscience? Veterans of numerous edit wars and talk page battles spanning dozens of articles across Wikipedia, User:Martinphi and User:ScienceApologist will go head to head on the subject of Wikipedia, Science, and Pseudoscience in a groundbreaking interview to be published in an upcoming issue of Signpost. User:Zvika will moderate the discussion. Post suggested topics and questions at The Martinphi-ScienceApologist Interview page. 66.30.77.62 (talk) 17:14, 12 March 2008 (UTC)
I'm worried
Hi Filll
As you've probably gathered, my special area of activity on Wikipedia is the Old Testament, especially the Pentateuch. My aim is to gradually (it has to be gradual - these articles are all controversial) bring them up to encyclopedia-standard by bringing modern biblical scholarship into the picture. (Have a look at my on-going re-write of Creation according to Genesis - once a stronghold og wide-eyed creationism, not increasingly scholarly, and not yet finished).
Anyway, a new link has appeared on Genesis. It's T Wikiversity: Study of Genesis. I never knew this thing existed. But apparently, in the democratic world of Wiki, not only can any ignoramus write encyclopedia articles to educate his equally ignorant fellows, he can also run university courses. This one, on the study of Genesis, is being run by a guy who woks in a Target store. Jesus wept.
So what to do? It won't just go away. And I can't say I disagree with the "courses" he's set out. But a guy from Target is going to assess papers? http://en.wikiversity.org/wiki/Study_of_Genesis/Project_Page/Sample_Term_Paper gives you the idea. I just don't know what to do. What do you suggest?
PiCo (talk) 05:41, 13 March 2008 (UTC)
- I am not sure. But I do know that if you look back at the early days of Wikipedia, it was a lot more wild and wooly. And anyone could just declare anything to be true. Then slowly there started to be standards. And sources were increasingly required. And if you look at a GA or FA from 2 or 3 years ago, it was a very different quality level than a GA or FA today. So although WP itself has plenty of problems of various kinds, the standards are improving. Other Wiki projects are not as well developed as WP itself. And one of those I suspect is Wikiversity. It is very early days for Wikiversity, clearly. There is no "accreditation" agency and no standards for courses. Anyone anywhere who wants to set up a course and run it, can. And you are nervous about having to advertise what you feel is substandard material on your increasingly sophisticated and professional article page, but do not want to be uncharitable. I would ask for advice at the Village Pump if I were you. Also, would a tiny link at the bottom really be such a disaster? People will quickly see what sort of resource it is for themselves if and when they look (although I suspect few yet go to look at things from Wikiversity, to be honest). You could just delete the link to it, although that is not particularly fair and he could complain.
- What I think will happen eventually is that there will be increasing competition in Wikiversity among those offering courses. And some sort of rating and ranking system will emerge. Some courses will be excluded, or pushed into other places. Another option is that Wikiversity just folds; after all, students have the increasing option to get real courses from MIT and Berkeley, including videos of lectures etc. And they will be joined by other schools. Why should anyone go to Wikiversity run by amateurs when they can get the real thing from world famous scholars, free of charge?--Filll (talk) 12:29, 13 March 2008 (UTC)
Another option is to discuss it on Wikiversity itself at their "Collquium"--Filll (talk) 12:54, 13 March 2008 (UTC)
You were dead right
about Amaltheus. Cheers! Wassupwestcoast (talk) 20:23, 14 March 2008 (UTC)
- I was? What do you know? Email me.--Filll (talk) 20:29, 14 March 2008 (UTC)
- Sorry, it isn't that conspiratorial. It is just that his entire time at Wikipedia bracketed the Into to Evol FAC. He hasn't contributed since 28 Jan 2008. Cheers! Wassupwestcoast (talk) 20:35, 14 March 2008 (UTC)
- You're right never trust the ones that just disappear: ;)
- 14:50, 3 March 2008 (hist) (diff) User talk:Wassupwestcoast (off break)
- 14:50, 3 March 2008 (hist) (diff) User:Wassupwestcoast (off break)
- 21:03, 11 February 2008 (hist) (diff) User:Wassupwestcoast (→Movies: wiki)
- 21:01, 11 February 2008 (hist) (diff) User:Wassupwestcoast (→Movies: movie update)
- And welcome back. David D. (Talk) 20:39, 14 March 2008 (UTC)
He was only here for fighting. When there was a "checkmate" situation and he was on the losing end, he vanished.--Filll (talk) 20:41, 14 March 2008 (UTC)
- Strange one for sure. David D. (Talk) 20:42, 14 March 2008 (UTC)
More to this than meets the eye, I suspect.--Filll (talk) 20:43, 14 March 2008 (UTC)
- Yup, I never trust me. Especially 'cause I can be a bit naive :-) So far the experience is number 1 on my list of Wikipedia weirdness. Cheers! Wassupwestcoast (talk) 20:47, 14 March 2008 (UTC)
I don't get it
Why would you say that? Do you think I'm going to block you or something. I'm very sorry if I've offended you in some way. I would be happy to collaborate with you. -GTBacchus(talk) 01:11, 17 March 2008 (UTC)
- The system has become more and more poisonous. One has to be extremely careful in the present circumstances because of the way the powers that be have decided WP must be. I cannot change it. I can only try to avoid getting into trouble. It is a shame, but we have decided that CIVIL is more important than anything else. And I can tell that this entire discussion has become so heated and unpleasant that it is too dangerous to continue.--Filll (talk) 01:36, 17 March 2008 (UTC)
- I strongly disagree that WP:CIVIL is more important than anything else, and I would never act as if it were. How have I ever given you the impression that I would behave that way? What kind of trouble do you think you'll get into? I have no desire to see you in trouble; I want to collaborate with you. Can you work with me, just a little bit? I'm not the "get you in trouble" type. We could use your help. -GTBacchus(talk) 01:42, 17 March 2008 (UTC)
- What sort of help could I offer? And you might not be someone who was interested in getting me in trouble, but there are plenty that are. I have had numerous warnings about this in the last 6 months or so, and I have watched Arbcomm's recent behavior on this issue. And I have observed how things have been moving on the pseudoscience pages. If we had to clean up the creationism pages today the way we did a year ago, it would be almost impossible today to do it given the current climate on Wikipedia, where the benefit of the doubt has to be given to those who are against NPOV and RS and LEAD and NOR and other WP policies. If you want to read more about this, take a look at some of what has been written here.--Filll (talk) 02:10, 17 March 2008 (UTC)
- The help you could offer is balance. You're familiar with the dispute and the sources. The fact of your contributing would help solidify whatever consensus we arrive at, because we would know that your input was considered fairly. You also have insight into a current problem with the political climate here. You could help change that. Help make Wikipedia a welcoming place for experts by helping me to empower users to deal with tendentious editors and trolls. That's precisely what I'm trying to do. We may disagree about causes of the atmosphere which you describe as increasingly poisonous, but we both want to do something about it. -GTBacchus(talk) 02:32, 17 March 2008 (UTC)
- What sort of help could I offer? And you might not be someone who was interested in getting me in trouble, but there are plenty that are. I have had numerous warnings about this in the last 6 months or so, and I have watched Arbcomm's recent behavior on this issue. And I have observed how things have been moving on the pseudoscience pages. If we had to clean up the creationism pages today the way we did a year ago, it would be almost impossible today to do it given the current climate on Wikipedia, where the benefit of the doubt has to be given to those who are against NPOV and RS and LEAD and NOR and other WP policies. If you want to read more about this, take a look at some of what has been written here.--Filll (talk) 02:10, 17 March 2008 (UTC)
Oh, regarding the expert withdrawal page, I know about that. I've read it. I agree with this view, and with this one. Oh, this is extremely good, too. I've actually left a comment there, and I have a question for you. You said: "The powers that be including Arbcomm are dead set against this and have made it clear that they will desysop any admin who does this." Can you give me a link for that, please? -GTBacchus(talk) 02:51, 17 March 2008 (UTC)
Please put this on the Talk:Homeopathy Page and mention it is posted by me
Dear Filll,
Please put this on the Talk:Homeopathy Page and mention it is posted by me (or else the others may think I've bribed you); I'm not yet able to post there directly myself because the Page is semi-writeprotected.
Here are some of the studies/clinical trials:-
STUDIES OF THE ACTIVITY OF HOMEOPATHIC MEDICINES
ORIGINAL/TRANSLATED TITLE | AUTHOR(S) | PUBLICATION | ACTIVITY | STUDY |
Inhibition of lymphoblast transformation test (LTT) in phytohaemagglutinin (PHA) with Phytolacca americana in homeopathic dilution |
Colas H., Aubin M., Picard P., Lebecq J.C. |
Ann. Homéopat. Fr., 1975, 6: 1-11. |
Inhibitory |
Lymphoblast transformation |
Inquiry into the limits of biological effects of chemical compounds in tissue culture. I. Low dose effects of mercure chloride |
Mansvelt J.D., van Amons E. |
Z. Naturtorschung,
1975, 30: 643-649. |
Inhibitory |
Lymphocyte growth |
The effects of Belladonna and Ferrum phosphoricum on the chemoluminescence of human poly-morphonuclear neutrophils |
Poitevin B., Aubin M., Royer J.F. |
Ann. Homéop. Fr.,
1983, 3: 5-12. |
Inhibitory |
Radical release |
Effect of aconitum and veratrum on the isolated perfused heart of the common eel (Anguilla anguilla) |
Pennec J.P., Aubin M. |
Comp. Biochem. Physiol., 1984, 776: 367-369. |
Protective | Aconitine toxicity |
Elements of homeopathic pharmacology |
Aubin M. |
Homéopathie Franç., 1984, 72: 231- 235 |
Protective | Aconitine toxicity |
The effect of homeopathic preparations on the phagocyte activity of granulocytes. In vitro tests and double-blind controlled trials |
Wagner H., Jurcic K., Doenicke A., Rosenhuber E., Behrens N. |
Arzneim. Forsch./Drug Res.,
1986, 36: 1424-1425. |
Stimulant | Phagocytosis |
Approach to quantitative analysis of the effect of Apis mellifica on the degranulation of human basophils cultivated in vitro |
Poitevin B., Aubin M., Benveniste J. |
Innov. Tech. Biol. Med., 1986, 7: 64-68. |
Inhibitory |
Basophil degranulation |
In vitro stimulation of human granulocytes and lymphocytes by pico- and femtogram quantities of cytostatic agents |
Wagner H., Kreher B., Jurcic K. |
Arzneim. Forsch./Drug Res., 1988, 38: 273-275. |
Stimulant |
Lymphocyte growth |
Human basophil degranulation triggered by very dilute antiserum against IgE |
Davenas E., Beauvais F., Amara J., Robinson M., Miadonna A., Tedeschi A., Pomeranz B., Fortner P., Belon P., Sainte-Laudy J., Poitevin B., Benveniste J. |
Nature, 1988, 333: 816-818. |
Stimulant |
Basophils |
In vitro immunological degranulation of human basophils is modulated by lung histamine and Apis mellifica |
Poitevin B., Davenas E., Benveniste J. |
Brit. J. Clin. Pharmacol., 1988, 25: 439-444. |
Inhibitory |
Basophil degranulation |
Cytotoxic agents as immunomodulators |
Wagner H., Kreher B. |
Proc. of the 3rd GIRI meeting, Paris, 1989, 31- 46. |
Stimulant |
Lymphocyte growth |
Contributions of fundamental research in homeopathy |
Boiron J., Belon P. |
Berl. J. Res. Hom.,
1990, 1: 34-35. |
Inhibitory |
Basophil degranulation |
Synergism of action between indoleacetic acid (IAA) and highly diluted solutions of CaCO3 on the growth of oat coleoptiles |
Bornoroni C. |
Berl. J. Res. Hom.,
1991, 1 (4/5): 275-278. |
Stimulant |
Growth of plant cells |
Study of the action of Hahnemannian dilutions of mercury chloride on the mitotic index in animal cell cultures. |
Boiron J., Abecassis J., Cotte J., Bernard A.M. |
Ann. Homéop. Fr., 1991, 23: 43-49. |
Protective | Hg toxicity |
Dual effects of formylpeptides on the adhesion of endotoxin-primed human neutrophils |
Bellavite P., Chirumbolo S., Lippi G., Andrioli G., Bonazzi L., Ferro I. |
Cell. Biochem. Funct., 1993, 11: 231-239. |
Inhibitory |
Cell adhesion (bact. pept. 10-8-10-9) |
Effects of homeopathic preparations of organic acids and of minerals on the oxidative metabolism of human neutrophils |
Chirumbolo S., Signorini A., Bianchi I., Lippi G., Bellavite P. |
Br. Hom. J., 1993, 82: 227-244. |
Inhibitory |
Leucocyte activation (metabolism) |
Platelets/endothelial cells interactions in presence of acetylsalicylic acid at ultra low dose |
Doutremepuich C., Lalanne M.C., Ramboer I., Sertillanges M.N., De Seze O. |
Omeomed 92 (C. Bornoroni, ed.),
1993, Editrice Compositori, Bologna: 109-115. |
Inhibitory |
Prostacyclin release |
Effect of high dilutions of epidermal growth factor (EGF) on in vitro
proliferation of keratinocyte and fibroblast cell lines |
Fougeray S., Moubry K., Vallot N., Bastide M. |
Br. Hom. J., 1993, 82: 124-125. |
Inhibitory |
Growth of keratinocytes |
Effects of different homeopathic potencies of Lachesis on lymphocyte cultures obtained from rabbit blood |
Enbergs H., Arndt G. |
Biol. Tier., 1993, 4. |
Stimulant |
Mitotic and immunostimulating activity (bact. pept 10-5-10-6) |
The effect of homeopathic potencies of housedust mite on the migration of house-dust sensitive human leukocytes |
Gibson S.L., Gibson R.G. |
Complement. Ther. Med., 1996, 4: 169-171. |
Stimulant |
Leucocyte chemotaxis |
The effects of Nux vomica Homaccord and Atropinum comp. on intestinal activity in vitro |
Kanui T.I., Enbergs H. |
Biol. Tier., 1996/1, 43-47. |
Stimulant |
Contraction of intestinal muscles |
Application of flow cytometry to the analysis of the immunosuppressive effect of histamine dilutions on human basophil action: effect of cimetidine |
Sainte-Laudy J., Belon P. |
Inflamm. Res.,
1997, 46: S27-S28. |
Inhibitory |
Basophil degranulation |
Effects of Podophillum pellatum compounds in various preparations and dilutions on human neutrophil functions in vitro |
Chirumbolo S., Conforti A., Lussignoli S., Metelmann H. et Al. |
Br. Hom. J., 1997; 86-16. |
Inhibitory |
Release of superoxides |
In vivo and in vitro studies on the efficiency of potentized and nonpotentized substances |
Harisch G., Dittmann J. |
BT, 1997, 2; 40-46. |
Difference between potentised and non-potentised substances |
In vivo and in vitro study; basic research |
Experiments with the effects of Ubichinon-Injeel and strong Ubichinon-Injeel on an acellular system |
Harisch G., Dittmann J. |
BM, 1997, 3; 99-104. |
Different effects of associations of various potencies and individual potencies |
In vitro study; basic research |
Efficacy of the homeopathic drugs Suis and Arnica comp.-Heel® on lymphocyte and phagocyte activity |
Enbergs H. |
BM, 1998, 1; 3-11. |
Effect of organotherapeutics and Arnica comp. - Heel® on immune system cells |
In vitro study; basic research |
Influence of dilutions and potencies of cAMP on different enzymatic systems |
Harisch G., Dittmann J. |
BM, 1998, 2; 55-62. |
Effects of dilutions and potencies of cAMP on some enzymatic activities |
In vitro study; basic research |
Studies of the principles of homeopathy; the changeover from in vivo to in vitro
experimental research |
Harisch G., Dittmann J. |
BM, 1998, 3; 98-103. |
Potentised and non-potentised dilutions are equally effective, but have different actions |
Basic research |
Determination of the activity of acid phosphatase with cAMP at various potencies |
Harisch G., Dittmann J. |
BM, 1999, 1; 4-8. |
Different effects on enzymatic activity |
In vitro study; basic research |
Contribution to study of the efficacy of homeopathic potencies of phosphorus |
Gomez J.C. |
BT, 1999, 2; 53-57. |
Effect of different potencies of phosphorus |
Tests on guinea pigs |
Determination of the activity of acid phosphatase in the presence of Ubichinon comp. |
Harisch G., Dittmann J. |
BM, 1999, 4; 188-194. |
Effect of enzymatic activity of homeopathic medicine |
Basic research |
Biochemical efficacy of homeopathic and electronic preparations of D8 potassium cyanate |
Dittmann J., Kanapin H., Harisch G. |
FKM, 1999, 6; 15-18. |
Homeopathic potentisation is more effective than electronic potentisation |
Basic research |
Osteoporosis in vitro in rat tibiaderived osteoblasts is promoted by the homeopathic preparation, FMS Calciumfluor |
Palermo C., Filanti C., Poggi S., Manduca P. |
Cell Biol Int, 1999, 23(1): 31-40. |
Stimulant |
Osteogenesis (trial with compound drug) |
Thin-layer chromatography (TLC) of homeopathic active constituents |
Schmolz M. |
BM, 1999, 5; 248-250. |
Constituents of Arnica comp.- Heel® ointment: electrophoresis accelerates their skin penetration. |
Basic research |
Effect of homeopathic
constituents on enzymatic activity. |
Basic research | |||
Efficacy of a potentised homeopathic drug in reducing cytotoxic effects produced by arsenic trioxide in mice |
Datta S., Mallick P., Bukhsh A.R. |
Complement Ther Med, 1999 Jan; 7 (8): 62-75 (a). |
Protective |
Arsenic trioxide toxicity |
Efficacy of a potentised homeopathic drug in reducing cytotoxic effects produced by arsenic trioxide in mice |
Datta S., Mallick P., Bukhsh A.R. |
Complement Ther Med, 1999 Sep; 7 (3): 156-63 (b). |
Protective |
Arsenic trioxide toxicity |
Non-cytotoxic antiviral action of a homeopathic drug |
Heine H. |
Ärzteitschrift für Neturheilverfahre,
2000; 41: 542-7. |
Stimulant |
ã interferon synthesis |
Efficacy of a potentised homeopathic drug in reducing cytotoxic effects produced by arsenic trioxide in mice |
Kundu S.N., Mitra K., Khuda Bukhsh A.R. |
Complement Ther Med , 2000 Sep; 1 (3): 157-65. |
Protective |
Arsenic trioxide toxicity |
Stimulatory effect of some plant extracts used in homeopathy on the phagocytosis induced chemiluminescence of polymorphonuclear leukocytes |
Crocnan D., Greabu M., Olinescu R. |
Rocz Akad Med Biochemist, 2000; 45: 246-254. |
Stimulant |
Phagocytosis |
Difference between the efficacy of single potencies and chords |
Dittmann J., Harisch G. |
BM, 2000, 1; 18-23. |
Potency chords are more effective than single potencies |
Basic research |
Influence of some homeopathic drugs on the catalytic activity of uricase, acid phosphatase and the cytosol glutathion-S-transferase |
Dittmann J., Kanapin H., Harisch G. |
BM, 2000, 3; 125-131 |
Effect of D8 potencies on three different enzymatic systems |
Basic research |
Influence of some homeopathic drugs on the catalytic activity of cAMP-dependent protein kinases |
Dittmann J., Kanapin H., Harisch G. |
BM, 2000, 6; 289-296. |
Effect of different potencies of 5 substances on enzymatic activity |
Basic research |
Neuroprotection from glutamate toxicity with ultra-low dose glutamate |
Jonas W., Lin Y., Zortella F. |
Neuroreport,
2001 Feb 92; 12 (2): 335-9. |
Protective | Glutamate toxicity |
KEY: BT = Biomedical Therapy
BM = Biologische Medizin
FKM = Forschung Komplementär Medizin
Ramaanand (talk) 02:14, 17 March 2008 (UTC)Dr.Jhingadé